In vitro studies indicated that erlotinib treatment inhibited IBC cell proliferation, anchorage-independent growth, cell motility, the COX-2 inflammatory pathway, and CSC marker-bearing cells in IBC [22,33]. The gene discussed is PTGS2; the disease is inflammatory breast carcinoma.